Home  About us  Contact
 

Membranous Nephropathy (membranous + nephropathy)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

HEPATITIS B VIRUS-RELATED MEMBRANOUS NEPHROPATHY TREATED WITH ENTECAVIR

NEPHROLOGY, Issue 2 2010
RYOTA IKEE
No abstract is available for this article. [source]

Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy

AMERICAN JOURNAL OF TRANSPLANTATION, Issue 5 2010
P. Cravedi
No abstract is available for this article. [source]

Recurrent Idiopathic Membranous Nephropathy: Early Diagnosis by Protocol Biopsies and Treatment with Anti-CD20 Monoclonal Antibodies

AMERICAN JOURNAL OF TRANSPLANTATION, Issue 12 2009
Ziad M. El-Zoghby
Membranous nephropathy (MN) recurs posttransplant in 42% of patients. We compared MN recurrence rates in a historical cohort transplanted between 1990 and 1999 and in a current cohort diagnosed by protocol biopsies, we analyzed the progression of the disease and we assessed the effects of anti-CD20 antibodies (Rituximab) on recurrent MN. The incidence of recurrent MN was similar in the historical (53%) and the current cohorts (41%), although in the later the diagnosis was made earlier (median, 4[2,21] months vs. 83[6,149], p = 0.002) and the disease was clinically milder. Twelve out of 14 patients (86%) with recurrent MN in the current cohort had progressive increases in proteinuria. Eight recipients were treated with Rituximab after their proteinuria increased from median, 211 mg/day (64,4898) at diagnosis to 4489 (898,13 855) (p = 0.038). Twelve months post-Rituximab, 75% of patients had either partial (PR) or complete remission (CR). After 24 months 6/7 (86%) had PR/CR and one patient relapsed. Posttreatment biopsies showed resorption of electron dense immune deposits in 6/7 cases and were negative for C3 (4/7) and IgG (3/7). Protocol biopsies allow early diagnosis of subclinical recurrent MN, which is often progressive. Treatment of recurrent MN with Rituximab is promising and should be evaluated in a prospective randomized controlled trial. [source]

Management of membranous nephropathy

NEPHROLOGY, Issue 4 2000
Daniel Cattran
SUMMARY: The Management of membranous nephropathy requires a recognition of its natural history and an ability to predict those pationts with the worst prognosis. Treatment of those at risk of progression with immunosuppressive drugs should be accompanied by additional conservative risk reduction strategies such as dietary protein restriction, blood pressure reduction, angiotensin-converting enzyme inhibitors and lipid-lowering agents. Anticoagulants should also be considered as well as medications to reduce drug toxicity. [source]